Skip to main content
Contact Us
Subscribe
E-Edition
39°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Y-mAbs Therapeutics, Inc. - Common Stock
(NQ:
YMAB
)
6.240
+0.070 (+1.13%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Y-mAbs Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Analyst Expectations for Y-mAbs Therapeutics's Future
July 25, 2023
Via
Benzinga
Where Y-mAbs Therapeutics Stands With Analysts
June 07, 2023
Via
Benzinga
B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know
May 15, 2023
Via
Benzinga
Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility
May 10, 2023
Wedbush has upgraded Y-mAbs Therapeutics Inc (NASDAQ: YMAB)to Outperform from Neutral, with a
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
May 10, 2023
Via
Benzinga
Preview: Y-mAbs Therapeutics's Earnings
May 05, 2023
Via
Benzinga
Earnings Outlook For Y-mAbs Therapeutics
March 29, 2023
Via
Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 09, 2023
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.
Via
Benzinga
Earnings Scheduled For May 8, 2023
May 08, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
April 03, 2023
Via
Benzinga
Crude Oil Rises 1.5%; Checkpoint Therapeutics Shares Slide
March 31, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping more than 200 points on Friday. The Dow traded up 0.72% to 33,095.32 while the NASDAQ rose 1.09% to 12,144.31. The S&P...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
March 31, 2023
Via
Benzinga
Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead
March 31, 2023
The Dow Jones Industrial Average is boasting a triple-digit lead this afternoon, as investors unpack this morning's flood of inflation data.
Via
Talk Markets
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 31, 2023
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.
Via
Benzinga
Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge
March 31, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 100 points on Friday. The Dow traded up 0.69% to 33,086.43 while the NASDAQ rose 1.01% to 12,134.43. The...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 31, 2023
Via
Benzinga
Why Chicken Soup for the Soul Entertainment Shares Are Trading Lower By 30%; Here Are 20 Stocks Moving Premarket
March 31, 2023
Gainers Ault Alliance, Inc. (NASDAQ: AULT) jumped 34.8% to $0.1265 in pre-market trading. Ault Alliance plans share buyback of up to 333.33 million shares of common stock at $0.15 per share through...
Via
Benzinga
Earnings Scheduled For March 30, 2023
March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
March 24, 2023
On Friday, 469 companies hit new 52-week lows.
Via
Benzinga
YMAB FINAL DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB
March 19, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Y-MABS THERAPEUTICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
March 17, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
YMAB FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securities Class Action – YMAB
March 17, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
March 17, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate
March 13, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
March 13, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
March 12, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
March 12, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
March 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
March 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
March 06, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.